Because the publication of your February 2022 compounding possibility inform, FDA has become aware of raising public desire in using sublingual and oral dosage kinds of compounded ketamine with the remedy of psychiatric disorders. FDA understands that the ability to obtain these products by means of telemedicine platforms and compounders https://ketalinic.com/about-us/